Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Coya Therapeutics, Inc. ( (COYA) ) has issued an announcement.
Coya Therapeutics announced its third-quarter financial results for 2025, highlighting significant corporate developments. The company received FDA acceptance for its Investigational New Drug (IND) application for COYA 302, aimed at treating Amyotrophic Lateral Sclerosis (ALS), and launched the ALSTARS Trial, a Phase 2 study for the same. Additionally, they reported promising preclinical results for COYA 303 and completed patient enrollment for a study on Frontotemporal Dementia (FTD). Financially, Coya closed a $23 million public offering, extending its cash runway into the second half of 2027. The company reported a net loss of $2.1 million for the quarter, a reduction from the previous year’s $4 million loss, with increased revenues and expenses attributed to the advancement of their clinical programs.
The most recent analyst rating on (COYA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
Coya Therapeutics, Inc. has a mixed outlook. Strong clinical progress and financial stability from a debt-free balance sheet with cash reserves are significant positives. However, persistent profitability and cash flow challenges weigh heavily on the overall score. Technical indicators suggest moderate momentum, while valuation remains pressured by ongoing losses. The company’s strategic advancements and funding efforts are positive but need to translate into improved financial performance to enhance the stock’s appeal.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc., headquartered in Houston, TX, is a clinical-stage biotechnology company focused on developing treatments that leverage regulatory T cells (Tregs) to address systemic inflammation and neuroinflammation. The company’s investigational product pipeline includes Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, targeting conditions such as neurodegenerative, metabolic, and autoimmune diseases.
Average Trading Volume: 162,435
Technical Sentiment Signal: Sell
Current Market Cap: $124.5M
Learn more about COYA stock on TipRanks’ Stock Analysis page.